Clinical Trial Update: PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS [Phase 2]

View source ↗

Summary

Phase II trial update of 5-Azacytidine plus valproic acid (and eventually ATRA) in intermediate II and high-risk myelodysplastic syndromes; study completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• 5-Azacytidine (5-azacytidine)
• ATRA (all-trans retinoic acid)
• VALPROIC ACID (Valproic acid)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2018-08-07